Table 2.
Use of carbapenems and other antibiotic classes in hospital wards across France, 2009–2013
| Antibiotic use, DDDs per 1000 patient-days (RC)a | ICU wards, N = 85 | Medical wards, N = 227 | Surgical wards, N = 181 |
|---|---|---|---|
| All antibiotics | 1487 (−0.52%) | 615 (−0.89%) | 607 (+ 5.68%) |
| Carbapenems | 73.4 (+ 5.65%) | 6.2 (+ 24.1%) | 5.4 (+ 25.1%) |
| - Imipenem | 62.1 (−0.74%) | 5.3 (+ 13.9%) | 4.2 (+ 27.5%) |
| - Meropenem | 5.3 (+ 285%) | 0.36 (+ 195%) | 0.23 (+ 109%) |
| - Ertapenem | 4.87 (−20.4%) | 0.52 (+ 45.3%) | 0.86 (− 13.3%) |
| - Doripenem | 1.17 (−16.7%) | 0.04 (+ 208%) | 0.06 (+ 1125%) |
| Aminopenicillins ± β-lactamase inhibitors | 417 (−2.86%) | 318 (−1.65%) | 268 (+ 0.94%) |
| Piperacillin/tazobactam | 90.1 (+ 34.7%) | 8.6 (+ 79%) | 8 (+ 109%) |
| Third-generation cephalosporins | 205.9 (+ 0.78%) | 60.4 (+ 18.9%) | 38.1 (+33.2%) |
| Fluoroquinolones | 177.2 (−24.2%) | 88.4 (− 21.3%) | 75.1 (−13.1%) |
| Aminoglycosides | 106.1 (+3.35%) | 12.4 (−6.98%) | 25.4 (+ 13.8%) |
| Glycopeptides | 59.6 (−23.2%) | 9.8 (−5.1%) | 10.3 (+ 23.6%) |
| Imidazoles | 61.9 (−3.93%) | 20.2 (+ 20.6%) | 39.6 (+ 9.96%) |
DDD defined daily dose; ICU intensive care unit; RC relative change (%) between 2009 and 2013
aPooled means in DDDs per 1000 patient-days and relative changes in percent